Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids

FDA's complete response letter includes extensive list of new studies needed to support abuse-deterrence claims not featured in two prior CRLs, Pain Therapeutics says, wondering why the agency is only now raising issues that could have been discussed previously.